Where does Nextkidney SA rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nextkidney SA ranks #41,939 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nextkidney SA hold?

Nextkidney SA holds 6 US utility patents granted between 2020 and 2025, spanning 2 technology areas.

What is Nextkidney SA's Innovation Score?

Nextkidney SA has an Innovation Score of 32.0 out of 100 (40th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Nextkidney SA's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Nextkidney SA.

What does claim depth mean for Nextkidney SA's patents?

Nextkidney SA's patents average 22.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nextkidney SA patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Nextkidney SA

Q: What technology areas does Nextkidney SA focus on?

Nextkidney SA's top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 6 patents. Grants appear in 2 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nextkidney ranks #41,939 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 2 technology areas.

#41,939
of 49,997 US assignees by volume: 40th percentile
by Innovation Score (32.0/100): 22.7
avg claims per patent

USPTO PatentsView assignee plate

Corpus R41939 · Foreign Corporation #41,939 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #41,939/49,997
PHOTO-FINISH Newtec CY
CPC-NARROW A61M · 2 areas
INNOV-THIN 32.0/100
CLAIMS-DENSE 22.7 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Newtec CY (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Nextkidney · this assignee

32
3D Lighting… · lowest

7

What this shows Nextkidney's Innovation Score is 32.0/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Nextkidney's grants concentrate

Nextkidney SA is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). By volume, Nextkidney sits between Newtec CY and NGR Inc..

Nextkidney's three-year grant acceleration

Nextkidney SA shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Newtec CY

6
Newtech Textile T…

6
Newvastek

6
Nexalin Technology

6
Nexus Industries

6
NG Imports

6
Ngcodec

6
NGR

6
Nextkidney ◀

6

What this shows Nextkidney holds 6 patents at rank #41,854, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nextkidney

By rank, the assignees closest to #41,854 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Nextkidney's primary technology class.

Nextkidney's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Nextkidney SA patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	16.7%
2021	1	16.7%
2023	1	16.7%
2024	1	16.7%
2025partial year	2	33.3%

Which technologies does Nextkidney SA patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 6

B01D - Separation 2

Top 2 of 2 technology areas

Where it ranks

Overall rank by patents

#41,939

of 49,997 tracked assignees

Innovation Score

32.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Nextkidney SA's patent record in context - here's where to go next.

Nextkidney SA's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #41,939 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nextkidney SA against Newtec CY, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.